Inhibition of the mTORC2 and chaperone pathways to treat leukemia.

Zhang, Fan; Lazorchak, Adam S; Liu, Dou; Chen, Fangping; Su, Bing

Zhang, Fan; Lazorchak, Adam S; Liu, Dou; Chen, Fangping; Su, Bing.

Affiliation

Zhang F; Department of Immunobiology and Vascular Biology and Therapeutic Program, Yale University School of Medicine, New Haven, CT 06520, USA.

Blood ; 119(25): 6080-8, 2012 Jun 21.

Article in En | MEDLINE | ID: mdl-22566604

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Leukemia/drug therapy; Molecular Chaperones/antagonists & inhibitors; Trans-Activators/antagonists & inhibitors; Animals; Benzoquinones/administration & dosage; Cells, Cultured; Drug Evaluation, Preclinical; HEK293 Cells; HSP90 Heat-Shock Proteins/antagonists & inhibitors; Humans; Indoles/administration & dosage; Jurkat Cells; Lactams, Macrocyclic/administration & dosage; Mice; Mice, Transgenic; Molecular Chaperones/metabolism; Purines/administration & dosage; Signal Transduction/drug effects; Signal Transduction/physiology; Sirolimus/administration & dosage; TOR Serine-Threonine Kinases/antagonists & inhibitors; Trans-Activators/metabolism; Transcription Factors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Leukemia / Antineoplastic Combined Chemotherapy Protocols / Trans-Activators / Molecular Chaperones Type of study: Prognostic_studies Language: En Journal: Blood Year: 2012 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google